CAS: 1476074-39-1
| Marke | Produktdaten | Reinheit | Preisklasse | Voraussichtliche Lieferung |
|---|---|---|---|---|
 | 4-Quinolinecarboxamide, N-methyl-8-[(1S)-1-methyl-2-[(2'-methyl[4,5'-bipyrimidin]-6-yl-4',6'-d2)amino]ethyl]- REF: IN-DA001F09CAS: 1476074-39-1 | % | Nachfragen | Do 12 Dez 24 |
 | VX-984 REF: TM-T11067CAS: 1476074-39-1 | 97.65% | 103,00 €~3.597,00 € | Do 13 Mär 25 |
![4-Quinolinecarboxamide, N-methyl-8-[(1S)-1-methyl-2-[(2'-methyl[4,5'-bipyrimidin]-6-yl-4',6'-d2)am…](https://static.cymitquimica.com/products/IN/thumb/DA001F09.jpg)
4-Quinolinecarboxamide, N-methyl-8-[(1S)-1-methyl-2-[(2'-methyl[4,5'-bipyrimidin]-6-yl-4',6'-d2)amino]ethyl]-
CAS:1476074-39-1
Formel:
C23H21D2N7O
Reinheit:
%
Molekulargewicht:
415.4873
Ref: IN-DA001F09
| 5mg | 180,00 € | ||
| 10mg | 302,00 € | ||
| 25mg | 567,00 € | ||
| 50mg | Nachfragen |
Voraussichtliche Lieferung in Vereinigte Staaten, am Donnerstag 12. Dezember 2024
VX-984
CAS:1476074-39-1
VX-984 (M9831) is an oral DNA-PK inhibitor, crossing the blood-brain barrier, targeting GBM and NSC-LC.
Formel:
C23H21D2N7O
Reinheit:
97.65%
Farbe und Form:
Solid
Molekulargewicht:
415.49
Ref: TM-T11067
| 1mg | 103,00 € | ||
| 5mg | 256,00 € | ||
| 10mg | 378,00 € | ||
| 25mg | 596,00 € | ||
| 50mg | 804,00 € | ||
| 100mg | 1.078,00 € | ||
| 200mg | 1.452,00 € | ||
| 1mL*10mM (DMSO) | 275,00 € |
Voraussichtliche Lieferung in Vereinigte Staaten, am Donnerstag 13. März 2025
